Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91038 | 0.88 | GRIA2 (0.47) | GRIA2CYP1A2 | |
| SCHEMBL90969 | 0.88 | GRIA2 (0.47) | GRIA2CYP1A2GRIA4 | |
| SCHEMBL91042 | 0.87 | ULK1 (0.43) | ULK1HSD11B1GRIA2CYP1A2 | |
| SCHEMBL90944 | 0.85 | USP30 (0.44) | USP30ULK1HSD11B1P2RY12MGLL | |
| SCHEMBL25148551 | 0.80 | USP30 (0.61) | USP30ULK1HSD11B1CYP1A2MGLL | |
| SCHEMBL90978 | 0.79 | DRD4 (0.48) | USP30GRIA2CYP1A2 | |
| SCHEMBL90956 | 0.76 | KDM4E (0.45) | USP30GRIA2CYP1A2GRIA4 | |
| SCHEMBL8594191 | 0.76 | KDM4E (0.45) | GRIA2CYP1A2GRIA4 | |
| SCHEMBL8528846 | 0.74 | RAB9A (0.40) | USP30HSD11B1GRIA2MGLL | |
| SCHEMBL91043 | 0.73 | GRM5 (0.46) | GRIA2CYP1A2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | USP30 4154/4885ULK1 4354/4885HSD11B1 1697/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | USP30 4154/4885ULK1 4354/4885HSD11B1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.